RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study
NCT: NCT07823465 · ENROLLING_BY_INVITATION
Brief Summary
The NeuroPace RNS System is FDA-approved for adults with drug-resistant focal epilepsy but is not yet approved for adolescents. This study uses real-world data to evaluate the RNS System's safety and effectiveness in adolescents aged 12 through 17 who have already received the device in routine clinical practice. Data will come from patient-authorized electronic health records and patient-reported outcomes collected through a central study site, not a traditional trial infrastructure. Up to 100 evaluable patients across the United States sites will be enrolled, with results intended to support expansion of the RNS System's approved indication to include this adolescent population.
Frequently Asked Questions
What is RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study?
RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study is a clinical trial registered under NCT07823465. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT07823465?
The current status of NCT07823465 (RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study) is: ENROLLING_BY_INVITATION.
When did RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study start?
RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study started on 2026-09-14.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.